We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
70
administered twice daily for two days
administered twice daily for two days
Stanford University Medical Center
Stanford, California, United States
RECRUITINGPrevention of ventilator-induced diaphragm dysfunction by JAK inhibition
Change in the force deficit that develops between the first and second muscle biopsies in the drug-treated vs. placebo groups
Time frame: 5-6 years
Increase in muscle strength due to JAK inhibition
Difference in force generated by muscle biopsies taken at time point 1 (pre-mechanical ventilation) from the drug-treated vs placebo groups
Time frame: 4-5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.